21
Jan

Novartis picked up FDA and European approvals to sell its secukinumab as a treatment for psoriasis, the first steps in the company’s plot to build a global anti-inflammatory contender and outpace its rivals.

…read more

Source: UPDATED: Novartis scores the first victory in a blockbuster psoriasis race

    

0 No comments